Azienda Ospedaliera Ordine Mauriziano Di Torino
Verified site
Turin, Italy
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
A clinical investigation is being conducted in people who have Food allergy, a condition in which the immune system reacts strongly to certain foods such as peanuts, milk, or egg, causing symptoms that can range from mild itching to severe breathing problems. The study evaluates the effect of an oral medication called remibrutinib (LOU064), which is taken twice daily, compared with an inactive tablet (placebo).
The purpose of the study is to determine whether the medication helps participants tolerate larger amounts of the allergenic foods without serious reactions. Over the course of about one year, participants are randomly assigned to receive either the active drug or the placebo, and neither they nor the study staff know which they receive (double‑blind). At several visits, participants undergo medically supervised food challenge tests in which increasing doses of peanut protein, milk protein, or egg protein are given to see the highest amount they can safely eat.
Throughout the trial, participants are closely monitored for any side effects, changes in vital signs, and overall health. The amount of each food protein that can be tolerated and the severity of any symptoms are recorded to assess the medication’s safety and effectiveness.
The trial runs in 9 steps – from screening to follow-up. Each step says what happens and what the team monitors.
6 criteria
5 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Turin, Italy
Rotterdam, The Netherlands
Utrecht, The Netherlands
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
an oral tablet that blocks a protein called BTK, which helps reduce allergic reactions. In this study participants take it to see if it lets them eat more of the food they are allergic to without having a reaction.
a powdered skimmed milk that is mixed into a drink for the test. It is given to participants to check how much milk protein they can tolerate while on the study medication.
a powdered form of ovalbumin (the main protein in egg whites). It is mixed into a drink and given to participants to see how much egg protein they can safely eat during the trial.
a powdered defatted peanut extract. It is mixed into a drink and used to test the amount of peanut protein participants can handle while taking the study drug.
a fast‑acting inhaled medicine that relaxes the muscles in the airways. It is kept on hand in case a participant develops breathing problems during the food challenge.
a medication given by injection that quickly treats severe allergic reactions (anaphylaxis). It is available as emergency treatment if a serious reaction occurs during the study.
This drug is taken as an oral film‑coated tablet that is swallowed whole. It is currently an investigational medicine being studied in clinical trials for allergic conditions such as food allergy. The main use being explored is to reduce allergic reactions by blocking a protein called Bruton’s tyrosine kinase, which helps stop immune cells from over‑reacting. It belongs to the class of Bruton’s tyrosine kinase (BTK) inhibitors, a type of targeted therapy.
Salbutamol is usually inhaled through a small inhaler device, delivering the medicine directly to the lungs. It is an approved, widely used drug for relieving asthma symptoms and other breathing problems caused by narrowed airways. It works by activating beta‑2 receptors in the airway muscles, causing them to relax and open up. Salbutamol is classified as a short‑acting beta‑2 agonist.
Epinephrine is given by injection, often with an auto‑injector that is pressed against the thigh. It is an approved emergency treatment for severe allergic reactions (anaphylaxis) and for cardiac arrest. The drug quickly narrows blood vessels and opens the airways by stimulating both alpha and beta receptors, helping the body recover from a life‑threatening reaction. Epinephrine is classified as a non‑selective adrenergic agonist.
The immune system reacts to proteins in peanuts, causing symptoms after ingestion. Reactions can start with mild itching and progress to more widespread symptoms if larger amounts are consumed. The condition is chronic; individuals remain sensitive over time. Exposure to even trace amounts can trigger symptoms. Symptoms may increase in severity with repeated exposures. The allergy typically begins in childhood but can persist.
This is an immune response to proteins in cow's milk that leads to symptoms after drinking or eating milk products. Early reactions may include skin redness or stomach upset, and with higher intake, symptoms can spread to other parts of the body. The sensitivity is usually present from infancy and may change over time. Small amounts can still cause a reaction. The condition can evolve, with some children outgrowing it while others continue to be affected.
The immune system reacts to proteins in egg whites or yolks, causing symptoms when eggs are consumed. Initial signs may be mild skin irritation, and larger exposures can lead to more extensive reactions. The allergy is often identified in early childhood and can persist. Even tiny quantities of egg protein may provoke a response. The pattern of reactions can vary with the amount and form of egg ingested.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.